Nathalie Lachenal

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Bern-Thomas Nyang’wa, Catherine Berry, Emil Kazounis et al. · The Lancet Respiratory Medicine · 2023 · 96 citations · Full text

Pharmacy, Pharmacotherapy, Antimicrobial Pharmacotherapy +12

Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis

Lorenzo Guglielmetti, Uzma Khan, Gustavo E. Velásquez et al. · New England Journal of Medicine · 2025 · 76 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort

Catherine Hewison, Uzma Khan, Mathieu Bastard et al. · Clinical Infectious Diseases · 2022 · 53 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17

Six-Month Response to Delamanid Treatment in MDR TB Patients

Cathy Hewison, Gabriella Ferlazzo, Zaza Avaliani et al. · Emerging infectious diseases · 2017 · 43 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +12

Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia

Catherine Hewison, Mathieu Bastard, Naira Khachatryan et al. · The International Journal of Tuberculosis and Lung Disease · 2018 · 41 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16